05.06.2013 - After having raised €19m, Belgian reg-med specialist Cardio3 BioSciences has hunger for more. The company announced to go public.
Only two weeks after a capital increase, the company said it will launch an IPO at NYSE Euronext Brussels and NYSE Euronext Paris to raise new funds. Cardio3 BioSciences' lead product C-CureR (C3BS-CQR-1) has been moved to Phase III development following promising results.
Through a process called cardiopoiesis, the company can reprogramme bone marrow cells to become heart precursor cells. Cardio3 BioSciences wants to use them to repair heart failure secondary to ischemic heart disease. The IP was licenced from the US Mayo Clinic (Rochester, Minnesota).
Heart failure is one of the world's greatest unmet medical needs. At 40 years old, a person has a one in five risk of developing heart failure and, once the disorder is apparent, a one in three chance of dying within a year of diagnosis. US$32bn annually is spent on heart failure patients in the US alone.
C3BS-CQR-1 is currently being tested in Europe in the CHART-1 trial, the world's first phase III trial using pre-programmed cardiac progenitor cells for the treatment of heart failure. Phase II results pointed to an increase of 25% of the Left Ventricular Ejection Fraction (LVEF) which was statistically significant (p<0.0001), as was the increase in exercise capacity measured by the 6 minutes Walking Distance test (+77m change at 6 months versus baseline in comparison to the control group (p<0.01). Cardio3 BioSciences intends to start a trial in the US (the CHART-2 trial if the FDA authorizes its start. The CHART programme is designed as two pivotal studies to obtain marketing authorisation in Europe and in the USA respectively, either alone, or in combination with other clinical trials.
28.01.2015 EMA recommends suspending around 750 generic medicines marketed throughout the world after India’s GVK Biosciences is accused of faking bioequivalence studies. Meds considered critically important for patients will remain available.
20.01.2015 Ebola research projects are set to receive €215m in funding from the European Commission’s IMI2 Ebola+ programme. Among the project partners are vaccine developers Glaxosmithkline, Johnson&Johnson and Merck.
13.01.2015 Shire beefs up its rare disease portfolio after acquiring NPS Pharma with the aim of becoming a leading biotech in a US$5.2bn deal. Part of the deal is the US biotech's lead portfolio of gastrointestinal and hormone replacement therapies.